Rivaroxaban: all 303 studies that test it
Page 1 of 4. Open to participants first (60), then studies with results posted, then the rest; newest registration first within each.
- Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee ArthroplastyRecruitingNCT07869615Not applicable
- Comparison of Aspirin Alone Versus Low-Dose Rivaroxaban Plus Aspirin in Chronic Limb-Threatening IschemiaRecruitingNCT07832578Early Phase 1
- Rivaroxaban vs Enoxaparin After Cesarean Section: Laboratory Thromboprophylaxis OutcomesRecruitingNCT07820670Not applicable
- Comparison of Clopidogrel-based Antiplatelet Agent Treatment and Aspirin Plus Low Dose Rivaroxaban TherapyRecruitingNCT07796217Phase 4
- Personalizing Thromboprophylaxis for Patients With Peripheral Artery DiseaseRecruitingNCT07613840Not applicable
- Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein ThrombosisNot yet recruitingNCT07602062Not applicable
- Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With Coronary Artery EctasiaRecruitingNCT07511257Phase 4
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)Not yet recruitingNCT07468448Phase 3
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart ValvesEnrolling by invitationNCT07456085Phase 3
- Rivaroxaban in Idiopathic Membranous NephropathyRecruitingNCT07404436Phase 4
- Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic MalignanciesRecruitingNCT07270263Not applicable
- Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT PreventionRecruitingNCT07243080Phase 4
- Hip Fracture Surgery Arterial and Venous Thrombotic Events PreventionNot yet recruitingNCT07228663Phase 3
- Rivaroxaban for Slow Coronary Flow After PCI in STEMINot yet recruitingNCT07195812Phase 4
- Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki DiseaseRecruitingNCT06978439Phase 4
- Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk ReductionRecruitingNCT06961630Early Phase 1
- Comparing the Safety and Efficacy of Apixaban and RivaroxabanRecruitingNCT06953726Phase 4
- VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb RevascularizationRecruitingNCT06873321Phase 4
- Excretion of Rivaroxaban in Human Breast MilkRecruitingNCT06831474Phase 1
- Effect of RIVAroxaban in Radial Artery Occlusion Treatment After Cardiac CatheterizationRecruitingNCT06812455Phase 4
- Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's SyndromeRecruitingNCT06780462Phase 3
- Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric SurgeryRecruitingNCT06689241Not applicable
- ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip ArthroplastyRecruitingNCT06611319Phase 3
- Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple MyelomaNot yet recruitingNCT06580223Phase 3
- Dabigatran Versus Rivaroxaban in Cerebral Venous ThrombosisRecruitingNCT06551402Phase 3
- Rivaroxaban Versus Apixaban in Cerebral Venous ThrombosisRecruitingNCT06531122Phase 3
- Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic ValvesNot yet recruitingNCT06476301Phase 4
- Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic StrokeNot yet recruitingNCT06396858Phase 4
- Thromboprophylaxis in Lower Limb ImmobilisationRecruitingNCT06370273Phase 3
- Pill-in-the-POCKET Oral Anticoagulation Strategy After AF Catheter AblationRecruitingNCT06216769Not applicable
- Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma PatientsRecruitingNCT06196918Not applicable
- RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTingRecruitingNCT06195540Phase 3
- Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial FibrillationRecruitingNCT06187311Phase 4
- Recanalization Rate of Acute DVTNot yet recruitingNCT06145269Early Phase 1
- Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial FibrillationRecruitingNCT06108414Phase 4
- Rivaroxaban Monotherapy After CYP2C19 Genotype Testing in Patients With Atrial Fibrillation and Percutaneous Coronary InterventionNot yet recruitingNCT06103266Phase 4
- Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and PolymorphismsRecruitingNCT06065592Phase 1
- Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical TrialRecruitingNCT05973188Phase 4
- Low-dose NOAC Versus GDMT After LAAORecruitingNCT05960721Not applicable
- VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic TherapyRecruitingNCT05920343Phase 2/3
- Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial InfarctionRecruitingNCT05892042Not applicable
- Anticoagulation in Post MI LV Thrombus Trial in NepalRecruitingNCT05794399Phase 4
- HIP Fracture Oral thromboPROphylaxis (Hip PRO Pilot)RecruitingNCT05775965Phase 2
- THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)RecruitingNCT05735639Phase 4
- Coronary Artery Ectasia, Efficacy of Various Anti Thrombotic Regimens.Not yet recruitingNCT05718531Phase 3
- Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic StenosisNot yet recruitingNCT05700266Phase 2/3
- Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki DiseaseRecruitingNCT05643651Phase 4
- NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCIRecruitingNCT05638867Phase 4
- Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism RiskNot yet recruitingNCT05487950Phase 4
- Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease PatientsRecruitingNCT05410275Phase 3
- Impact of Bromocriptine on Clinical Outcomes for Peripartum CardiomyopathyRecruitingNCT05180773Phase 4
- Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome PatientsRecruitingNCT05116995Phase 4
- Primary Thromboprophylaxis in Patients With Malignancy and Central Venous CathetersRecruitingNCT05029063Phase 3
- Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver CirrhosisRecruitingNCT04874428Phase 1
- Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein StentingRecruitingNCT04694248Not applicable
- COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial FibrillationRecruitingNCT04642430Phase 4
- Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary EmbolismRecruitingNCT04263038Phase 4
- Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve ReplacementRecruitingNCT04258488Phase 4
- Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS StudyRecruitingNCT04067505Phase 3
- Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava FiltersRecruitingNCT04066764Phase 3
- Xarelto for Thromboprophylaxis After Total Hip and Total Knee ArthroplastyCompletedNCT05449327Not applicableResults posted
- WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?CompletedNCT04990791Phase 4Results posted
- An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)CompletedNCT04970381Not applicableResults posted
- A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) InfectionTerminatedNCT04508023Phase 3Results posted
- A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)TerminatedNCT04504032Phase 2Results posted
- Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery DiseaseCompletedNCT04006288Phase 4Results posted
- Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health VolunteersCompletedNCT03864406Phase 1Results posted
- Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet TherapiesCompletedNCT03718429Phase 4Results posted
- Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial FibrillationCompletedNCT03702582Phase 3Results posted
- Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)CompletedNCT03578146Phase 2Results posted
- Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous LinesCompletedNCT03506815Phase 3Results posted
- Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous ThromboembolismCompletedNCT03266783Phase 4Results posted
- Comparison of Oral Anticoagulants for Extended VEnous ThromboembolismTerminatedNCT03196349Phase 4Results posted
- Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan ProcedureCompletedNCT02846532Phase 3Results posted
- Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)CompletedNCT02833948Phase 3Results posted
- RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual BleedingCompletedNCT02829957Phase 2/3Results posted
- Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in CancerCompletedNCT02744092Not applicableResults posted
- DOACs for Stroke Prevention Post Ventricular Tachycardia AblationCompletedNCT02666742Phase 4Results posted
- A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency DepartmentCompletedNCT02584660Phase 4Results posted
- Rivaroxaban for Treatment in Venous or Arterial Thrombosis in NeonatesCompletedNCT02564718Phase 1/2Results posted
- Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot StudyCompletedNCT02559856Phase 4Results posted
- Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical OutcomesTerminatedNCT02556203Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer ParticipantsCompletedNCT02555878Phase 3Results posted
- XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed ThrombolysisTerminatedNCT02506985Phase 4Results posted
- Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower ExtremitiesCompletedNCT02504216Phase 3Results posted
- Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary CalciumCompletedNCT02376010Phase 4Results posted
- Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)TerminatedNCT02313909Phase 3Results posted
- EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous ThrombosisCompletedNCT02309411Phase 2Results posted
- A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary SyndromeCompletedNCT02293395Phase 2Results posted
- Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb IschemiaCompletedNCT02260622Phase 2Results posted
- EINSTEIN Junior: Oral Rivaroxaban in Children With Venous ThrombosisCompletedNCT02234843Phase 3Results posted
- Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular RiskCompletedNCT02164578Phase 3Results posted
- A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge PatientsCompletedNCT02111564Phase 3Results posted
- The Effect of Rivaroxaban in Sickle Cell DiseaseCompletedNCT02072668Phase 2Results posted
- Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)CompletedNCT02064439Phase 3Results posted
- Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial FibrillationCompletedNCT02042534Phase 2Results posted
- A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart FailureCompletedNCT01877915Phase 3Results posted
- A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary InterventionCompletedNCT01830543Phase 3Results posted
- Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery DiseaseCompletedNCT01776424Phase 3Results posted
- A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation TherapyCompletedNCT01729871Phase 3Results posted